<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Selective inhibitors of cyclooxygenase (COX)-2 increase the risk of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and thrombotic events, but the responsible mechanisms are not fully understood </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: We found that <z:chebi fb="2" ids="30808">ferric chloride</z:chebi>-induced arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation was significantly greater in COX-2 knockout compared with <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="2" pm="."><plain>Cross-transfusion experiments excluded the likelihood that COX-2 knockout platelets, despite enhanced aggregation responses to collagen and thrombin, are responsible for increased arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in COX-2 knockout mice </plain></SENT>
<SENT sid="3" pm="."><plain>Importantly, we observed that COX-2 deletion decreased prostacyclin synthase and production and peroxisome proliferator-activated receptor- and sirtuin-1 (SIRT1) expression, with consequent increased upregulation of tissue factor (TF), the primary initiator of blood coagulation </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment of <z:mp ids='MP_0002169'>wild-type</z:mp> mice with a prostacyclin receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> or a peroxisome proliferator-activated receptor-δ <z:chebi fb="68" ids="48706">antagonist</z:chebi>, which predisposes to <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, decreased SIRT1 expression and increased TF activity </plain></SENT>
<SENT sid="5" pm="."><plain>Conversely, exogenous prostacyclin or peroxisome proliferator-activated receptor-δ <z:chebi fb="4" ids="48705">agonist</z:chebi> completely reversed the thrombotic phenotype in COX-2 knockout mice, restoring <z:mpath ids='MPATH_458'>normal</z:mpath> SIRT1 levels and reducing TF activity </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, inhibition of SIRT1 increased TF expression and activity and promoted generation of occlusive <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in <z:mp ids='MP_0002169'>wild-type</z:mp> mice, whereas SIRT1 activation was sufficient to decrease abnormal TF activity and prothrombotic status in COX-2 knockout mice </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Modulation of SIRT1 and hence TF by prostacyclin/peroxisome proliferator-activated receptor-δ pathways not only represents a new mechanism in controlling arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation but also might be a useful target for therapeutic intervention in the atherothrombotic complications associated with COX-2 inhibitors </plain></SENT>
</text></document>